Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07337616 · ClinicalTrials.gov registry record · NA

Field Shield Wound Dressing Study

A NA study of Burn Wounds - Partial Thickness (2nd Degree), sponsored by KeriCure Medical.

Recruiting
Registry status
NA
Development phase
40
Enrollment target
2
Study locations

NCT07337616: Recruiting NA study of Burn Wounds - Partial Thickness (2nd Degree), sponsored by KeriCure Medical.

NCT07337616 is a NA study of Burn Wounds - Partial Thickness (2nd Degree) that is actively recruiting participants, run by KeriCure Medical. The registered enrollment target is 40 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07337616, a NA study of Burn Wounds - Partial Thickness (2nd Degree), is actively recruiting participants, sponsored by KeriCure Medical.

RECRUITING
Registry status
NA
Development phase
40 participants
Enrollment target
2
Study locations

Study Summary

This study is to compare the Field Shield Wound Dressing (FSWD) as a treatment for burn wounds to a standard of care burn wound dressing to evaluate healing, infection, pain/discomfort, and deepening of wound over time.

Primary Outcome

Wound closure will be assessed at each time point (day 3, 7, 12, 19, 28, 35). The probability of wound closure will be assessed with a cluster randomized Generalized Estimating Equations (GEE) model of the probability of closure in terms of treatment and clinical site with clustering by patient and login link.

Interventions

  • DEVICE Field Shield Wound Dressing
  • DEVICE Silverlon

Study Locations (2)

Arizona

  • Valleywise Health - Phoenix

Texas

  • United State Army Institute of Surgical Research - San Antonio

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2025-05-01
Est. Completion 2026-09-29
Phase NA
KeriCure Medical

1 total trials

What NCT07337616 shows while recruiting

NCT07337616 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Burn Wounds - Partial Thickness (2nd Degree) appearing as the primary indexed condition, and to 2 interventions - of which Field Shield Wound Dressing is the first listed.

NCT07337616 reports a single indexed study location in Arizona, Texas.

Frequently Asked Questions

What is clinical trial NCT07337616 about?

NCT07337616 is a clinical study titled "Field Shield Wound Dressing Study". This study is to compare the Field Shield Wound Dressing (FSWD) as a treatment for burn wounds to a standard of care burn wound dressing to evaluate healing, infection, pain/discomfort, and deepening of wound over time.

What is the current status of trial NCT07337616?

This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2025-05-01. Estimated completion is 2026-09-29.

What conditions does trial NCT07337616 study?

This clinical trial studies the following conditions: Burn Wounds - Partial Thickness (2nd Degree).

What interventions are being tested in trial NCT07337616?

The interventions under investigation include: Field Shield Wound Dressing (DEVICE), Silverlon (DEVICE).

Who is sponsoring clinical trial NCT07337616?

This trial is sponsored by KeriCure Medical, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07337616 being conducted?

This trial has 2 study locations across Arizona, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

How this trial's enrollment target compares

Where NCT07337616's enrollment target sits among peer trials

40 1448th of 2000 higher than 465 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07337616, the US trial registry maintained by the National Library of Medicine. NCT07337616 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.